Bide Pharmatech (688073)2024-04-29 07:42Financial Performance - In Q1 2024, the company achieved operating revenue of CNY 263 million, a year-on-year increase of 4.05% [1] - The net profit attributable to shareholders was CNY 26.07 million, with a quarter-on-quarter increase of CNY 29.90 million [1] - The non-recurring net profit was CNY 25.43 million, up CNY 10.41 million quarter-on-quarter [1] - Operating cash flow was CNY 48.17 million, turning from negative to positive, with a year-on-year increase of CNY 69.63 million [2] Market and Customer Insights - In Q1 2024, overseas revenue reached CNY 148 million, indicating potential for further growth [2] - The number of active domestic customers increased to over 3,800, a year-on-year growth of 13.25% [2] - The number of publications using the company's products reached over 2,600 in 2023, with a significant increase in the number of publications to over 5,100 [2] Dividend and Profit Distribution - For the fiscal year 2023, the company reported a net profit of CNY 109.57 million, with an unallocated profit of CNY 150.68 million as of year-end [3] - The proposed cash dividend is CNY 0.90 per share (before tax), with a total cash dividend amounting to CNY 79.88 million, representing 72.90% of the annual net profit [3] Future Strategies - The company plans to enhance management efficiency by optimizing inventory and processes to reduce costs and improve net profit margins [2] - Future product development will focus on expanding product lines and improving synthesis processes, with an emphasis on customer needs [4] - The company aims to strengthen its global presence by establishing regional centers in key drug development areas and increasing business development personnel in overseas markets [5] Share Buyback and Employee Incentives - As of the report date, the company has repurchased 2,129,043 shares, accounting for 2.34% of the total share capital [4] - The management is currently discussing incentive plans for employees, with future disclosures planned as per legal requirements [4]